NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
The regimen — which consisted of teclistamab (JNJ-64007957, Janssen), subcutaneous daratumumab (Darzalex Faspro, Janssen) and lenalidomide (Revlimid, BMS) — also appeared well-tolerated, according to researchers.
Healio spoke with investigator Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, consultant hematologist at The Christie Hospital NHS Foundation Trust and honorary senior lecturer at University of
